Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
δ Opioid Receptor/DOR
|
---|---|
ln Vitro |
In vitro, gentamicin-induced renal epithelial cell death is attenuated by dalagin (100 µg/mL; 1 h) [2].
|
ln Vivo |
Rats exposed to gentamicin-induced renal damage demonstrate renoprotective effects when given dalaglinin (25, 50 µg/kg; ip)[2].
|
Cell Assay |
Cell Viability Assay[2]
Cell Types: Kidney cells Tested Concentrations: 100 µg/mL Incubation Duration: 1 h (prior to treatment with 1.2–2.5 mg/ml gentamicin for 24 h) Experimental Results: diminished kidney cell death. |
Animal Protocol |
Animal/Disease Models: 290-350 g, White male rats[2]
Doses: 25, 50 µg/kg Route of Administration: Ip (3 h before each gentamicin injection) Experimental Results: Mitigated gentamicin-induced acute kidney injury, attenuated ROS generation and oxidative stress, alleviated histopathological changes in a renal tissue. |
References |
[1]. Titov MI, et al. Dalargin--a peptidnyĭ preparat s tsitoprotektivnym deĭstviem [Dalargin--a peptide preparation with cytoprotective action]. Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR. 1985;8(2):72-6.
[2]. Plotnikov EY, et al. Nephroprotective effect of GSK-3β inhibition by lithium ions and δ-opioid receptor agonist dalargin on gentamicin-induced nephrotoxicity. Toxicol Lett. 2013 Jul 18;220(3):303-8. [3]. Polonskiĭ VM, et al. Mesto prilozheniia (tsentral'noe ili perifericheskoe) protivoiazvennogo deĭstviia sinteticheskogo analoga éndogennykh opioidov dalargina v éksperimental'noĭ modeli tsisteaminovykh duodenal'nykh iazv u krys [The site (central or peripheral) of the anti-ulcer action of dalargin, a synthetic analog of endogenous opioids in an experimental model of cysteamine-induced duodenal ulcer in rats]. Biull Eksp Biol Med. 1987 Apr;103(4):433-4. |
Molecular Formula |
C35H51N9O8
|
---|---|
Molecular Weight |
725.83
|
CAS # |
81733-79-1
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
FC(C(=O)O)(F)F.O=C([C@H](CC(C)C)NC([C@H](CC1C=CC=CC=1)NC(CNC([C@@H](C)NC([C@H](CC1C=CC(=CC=1)O)N)=O)=O)=O)=O)N[C@H](C(=O)O)CCC/N=C(\N)/N
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.3777 mL | 6.8887 mL | 13.7773 mL | |
5 mM | 0.2755 mL | 1.3777 mL | 2.7555 mL | |
10 mM | 0.1378 mL | 0.6889 mL | 1.3777 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.